Lonetti, A.; Indio, V.; Laginestra, M.A.; Tarantino, G.; Chiarini, F.; Astolfi, A.; Bertuccio, S.N.; Martelli, A.M.; Locatelli, F.; Pession, A.;
et al. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. Cancers 2020, 12, 1972.
https://doi.org/10.3390/cancers12071972
AMA Style
Lonetti A, Indio V, Laginestra MA, Tarantino G, Chiarini F, Astolfi A, Bertuccio SN, Martelli AM, Locatelli F, Pession A,
et al. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. Cancers. 2020; 12(7):1972.
https://doi.org/10.3390/cancers12071972
Chicago/Turabian Style
Lonetti, Annalisa, Valentina Indio, Maria Antonella Laginestra, Giuseppe Tarantino, Francesca Chiarini, Annalisa Astolfi, Salvatore N. Bertuccio, Alberto M. Martelli, Franco Locatelli, Andrea Pession,
and et al. 2020. "Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML" Cancers 12, no. 7: 1972.
https://doi.org/10.3390/cancers12071972
APA Style
Lonetti, A., Indio, V., Laginestra, M. A., Tarantino, G., Chiarini, F., Astolfi, A., Bertuccio, S. N., Martelli, A. M., Locatelli, F., Pession, A., & Masetti, R.
(2020). Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML. Cancers, 12(7), 1972.
https://doi.org/10.3390/cancers12071972
